Status:
NOT_YET_RECRUITING
Pharmacogenetic Testing at Community Pharmacy
Lead Sponsor:
Chantal Csajka
Conditions:
Pharmacogenetic Testing
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to assess the clinical impact of reducing treatment failure rates after using genetic information targeting CYP2C19 in validating escitalopram prescription. 5 pharmacies i...
Detailed Description
Response to medication depends on many clinical, demographic, environmental, and genetic factors. Non-genetic factors that are often considered when prescribing treatments address not only drug-drug i...
Eligibility Criteria
Inclusion
- Must consent to participate in the study,
- Must sign consent,
- Must be able to follow and understand the study procedures,
- Initiation of escitalopram treatment for unipolar depression with or without anxiety
Exclusion
- Other condition than depression (such as panic disorder)
- Escitalopram treatment already received
- Not able to consent to participate in the study.
Key Trial Info
Start Date :
August 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 14 2027
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT06210321
Start Date
August 15 2025
End Date
August 14 2027
Last Update
June 5 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.